Share on StockTwits

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) have received an average recommendation of “Buy” from the nineteen analysts that are presently covering the stock, AnalystRatings.Net reports. Two equities research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $148.86.

Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 115.40 on Tuesday. Valeant Pharmaceuticals Intl has a one year low of $94.55 and a one year high of $153.10. The stock’s 50-day moving average is $122.3 and its 200-day moving average is $130.7. The company’s market cap is $38.706 billion.

Valeant Pharmaceuticals Intl (NYSE:VRX) last released its earnings data on Thursday, July 31st. The company reported $1.91 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $1.91. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 86.2% on a year-over-year basis. Analysts expect that Valeant Pharmaceuticals Intl will post $8.03 EPS for the current fiscal year.

A number of research firms have recently commented on VRX. Analysts at Susquehanna cut their price target on shares of Valeant Pharmaceuticals Intl to $160.00 in a research note on Friday. Separately, analysts at Piper Jaffray cut their price target on shares of Valeant Pharmaceuticals Intl from $151.00 to $135.00 in a research note on Friday. Finally, analysts at CIBC cut their price target on shares of Valeant Pharmaceuticals Intl from $160.00 to $155.00 in a research note on Friday.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.